Simplex Trading’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.64K | Sell |
1,900
-1,500
| -44% | -$2.06K | ﹤0.01% | 8262 |
|
|
2025
Q4 | $5.47K | Sell |
3,400
-97,900
| -97% | -$205K | ﹤0.01% | 7382 |
|
|
2025
Q3 | $276K | Buy |
101,300
+10,300
| +11% | +$34.3K | ﹤0.01% | 4575 |
|
|
2025
Q2 | $331K | Sell |
91,000
-104,100
| -53% | -$286K | ﹤0.01% | 3954 |
|
|
2025
Q1 | $374K | Buy |
195,100
+60,000
| +44% | +$122K | ﹤0.01% | 3713 |
|
|
2024
Q4 | $256K | Buy |
135,100
+110,300
| +445% | +$192K | ﹤0.01% | 4241 |
|
|
2024
Q3 | $32K | Sell |
24,800
-72,600
| -75% | -$96.9K | ﹤0.01% | 6287 |
|
|
2024
Q2 | $99K | Sell |
97,400
-72,800
| -43% | -$90K | ﹤0.01% | 5380 |
|
|
2024
Q1 | $311K | Buy |
170,200
+160,900
| +1,730% | +$257K | ﹤0.01% | 4342 |
|
|
2023
Q4 | $11K | Sell |
9,300
-6,500
| -41% | -$6.63K | ﹤0.01% | 7338 |
|
|
2023
Q3 | $18K | Buy |
15,800
+12,400
| +365% | +$15.9K | ﹤0.01% | 6690 |
|
|
2023
Q2 | $3K | Buy |
3,400
+1,000
| +42% | +$965 | ﹤0.01% | 8164 |
|
|
2023
Q1 | $1K | Sell |
2,400
-600
| -20% | -$458 | ﹤0.01% | 8624 |
|
|
2022
Q4 | $1K | Sell |
3,000
-11,300
| -79% | -$3.54K | ﹤0.01% | 8742 |
|
|
2022
Q3 | $4K | Buy |
14,300
+4,000
| +39% | +$1.57K | ﹤0.01% | 8872 |
|
|
2022
Q2 | $3K | Sell |
10,300
-147,800
| -93% | -$62K | ﹤0.01% | 9100 |
|
|
2022
Q1 | $113K | Buy |
158,100
+141,100
| +830% | +$302K | ﹤0.01% | 5967 |
|
|
2021
Q4 | $38K | Sell |
17,000
-16,100
| -49% | -$43.9K | ﹤0.01% | 7585 |
|
|
2021
Q3 | $128K | Hold |
33,100
| – | – | ﹤0.01% | 6268 |
|
|
2021
Q2 | $125K | Buy |
33,100
+32,224
| +3,679% | +$108K | ﹤0.01% | 6406 |
|
|
2021
Q1 | $296K | Buy |
876
+151
| +21% | +$544 | ﹤0.01% | 4158 |
|
|
2020
Q4 | $203K | Sell |
725
-229
| -24% | -$669 | ﹤0.01% | 4577 |
|
|
2020
Q3 | $239K | Buy |
954
+849
| +809% | +$7.45K | ﹤0.01% | 3878 |
|
|
2020
Q2 | $142K | Sell |
105
-232
| -69% | -$2.4K | ﹤0.01% | 4400 |
|
|
2020
Q1 | $255K | Buy |
337
+1
| +0.3% | +$8 | ﹤0.01% | 3308 |
|
|
2019
Q4 | $212K | Buy |
336
+304
| +950% | +$1.45K | ﹤0.01% | 3689 |
|
|
2019
Q3 | $12K | Sell |
32
-5
| -14% | -$21 | ﹤0.01% | 6126 |
|
|
2019
Q2 | $17K | Sell |
37
-34
| -48% | -$193 | ﹤0.01% | 5723 |
|
|
2019
Q1 | $58K | Buy |
71
+34
| +92% | +$233 | ﹤0.01% | 4880 |
|
|
2018
Q4 | $19K | Sell |
37
-55
| -60% | -$430 | ﹤0.01% | 5352 |
|
|
2018
Q3 | $81K | Buy |
92
+60
| +188% | +$537 | ﹤0.01% | 4650 |
|
|
2018
Q2 | $31K | Buy |
32
+14
| +78% | +$140 | ﹤0.01% | 5501 |
|
|
2018
Q1 | $10K | Sell |
18
-2
| -10% | -$28 | ﹤0.01% | 3998 |
|
|
2017
Q4 | $5K | Buy |
+20
| New | +$332 | ﹤0.01% | 4451 |
|
|
2017
Q3 | – | Sell |
-96
| Closed | -$2K | – | 5810 |
|
|
2017
Q2 | $2K | Buy |
96
+33
| +52% | +$418 | ﹤0.01% | 5172 |
|
|
2017
Q1 | $4K | Sell |
63
-343
| -84% | -$3.35K | ﹤0.01% | 4719 |
|
|
2016
Q4 | $13K | Buy |
406
+246
| +154% | +$2.12K | ﹤0.01% | 3448 |
|
|
2016
Q3 | $1K | Sell |
160
-243
| -60% | -$2.07K | ﹤0.01% | 5219 |
|
|
2016
Q2 | $29K | Buy |
403
+203
| +102% | +$1.77K | ﹤0.01% | 2545 |
|
|
2016
Q1 | $25K | Buy |
200
+79
| +65% | +$641 | ﹤0.01% | 2585 |
|
|
2015
Q4 | $13K | Buy |
121
+96
| +384% | +$980 | ﹤0.01% | 3052 |
|
|
2015
Q3 | $4K | Buy |
+25
| New | +$229 | ﹤0.01% | 4098 |
|
Other funds holding AKBA
VCM
VPM
Simplex Trading's AKBA Position: Q1 2026 in Review
Simplex Trading reduced its Akebia Therapeutics (AKBA) stake by 49% in Q1 2026, selling an estimated $14.2K and leaving 10,589 shares worth $14.7K. The position accounts for ﹤0.01% of the portfolio, ranked #7011.
Simplex Trading first reported a position in AKBA in Q3 2015 and has held it in 30 quarters since. The position peaked at $883K in Q1 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Simplex Trading held 10,589 shares of Akebia Therapeutics worth $14.7K as of Q1 2026.
- Simplex Trading sold 10,306 Akebia Therapeutics shares in Q1 2026, an estimated $14.2K.
- Akebia Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #7011 holding.
- Simplex Trading first reported a position in Akebia Therapeutics in Q3 2015 and has held it in 30 quarters since.
- Simplex Trading's Akebia Therapeutics position peaked at $883K in Q1 2020.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.